FDA rejects liver cancer drug combo, shares of Korean biotech tank
Korean biotech HLB and its China-based partner Jiangsu Hengrui Pharmaceuticals said Friday that the FDA rejected their drug combination for the most common form of liver cancer. The FDA rejected the pairing of rivoceranib and …